SCHEMBL24975699

SCHEMBL24975699

CC(C)(O)c1ccc2ncc(I)n2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 3/20 0.37
PARP1 P09874 3/20 0.37
TNKS2 Q9H2K2 3/20 0.37
RIPK2 O43353 1/20 0.35
PIK3CA P42336 2/20 0.34
MTOR P42345 2/20 0.34
CYP11B2 P19099 6/20 0.33
CYP11B1 P15538 5/20 0.33
PIK3CD O00329 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
TGFBR1 P36897 4/20 0.32
ADORA3 P0DMS8 1/20 0.31
SLC6A3 Q01959 1/20 0.31
PARP6 Q2NL67 1/20 0.31
PARP10 Q53GL7 1/20 0.31
TIPARP Q7Z3E1 1/20 0.31
PARP8 Q8N3A8 1/20 0.31
PARP12 Q9H0J9 1/20 0.31
PARP11 Q9NR21 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31000200 0.84 CYP11B1 (0.35) CYP11B2CYP11B1EIF2AK4CYP2C9
SCHEMBL24975703 0.81 TNKS (0.41) TNKSPARP1TNKS2RIPK2PIK3CA
SCHEMBL16460211 0.79 ALDH1A1 (0.41) ALDH1A1EIF2AK4
SCHEMBL3321654 0.75 GABRA1 (0.43) CYP11B2CYP11B1ALDH1A1HPGD
SCHEMBL13336367 0.73 CYP1A2 (0.53) CYP11B2CYP11B1ALDH1A1HPGDCYP1A2
SCHEMBL25045604 0.72 CYP1A2 (0.33) CYP1A2CYP2C9
SCHEMBL1347462 0.71 SCN5A (0.55)
SCHEMBL31000273 0.70 EIF2AK4 (0.43) RIPK2PIK3CAMTORCYP11B2CYP11B1
SCHEMBL30935695 0.70 TGFBR1 (0.51) TNKSPARP1TNKS2RIPK2PIK3CA
SCHEMBL26927485 0.70 ALDH1A1 (0.49) RIPK2PIK3CDPIK3CGALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658659-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Children's Hospital Medical Center (US) 2025-12-10 EP disclosed
US-20250154144-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDRENS HOSPITAL MED CT (US) 2025-05-15 US disclosed
WO-2024163764-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2024-08-08 WO disclosed
WO-2023009833-A9 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-11-23 WO disclosed
WO-2023009833-A9 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-11-23 WO disclosed
WO-2023009833-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154144-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK3 TNKS 306/4885PARP1 229/4885TNKS2 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.